Moleculin Biotech (MBRX) EPS (Basic) Growth (5y) (2021 - 2026)
Moleculin Biotech (MBRX) EPS (Basic) Growth (5y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Moleculin Biotech | 3.35 Mn | 3.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 54.66% |
| Dec 31, 2025 | 42.36% |
| Sep 30, 2025 | 49.74% |
| Jun 30, 2025 | 45.43% |
| Mar 31, 2025 | 41.30% |
| Dec 31, 2024 | 25.38% |
| Sep 30, 2024 | 25.12% |
| Jun 30, 2024 | 35.63% |
| Mar 31, 2024 | 28.91% |
| Dec 31, 2023 | 14.09% |
| Sep 30, 2023 | 15.11% |
| Jun 30, 2023 | 29.93% |
| Mar 31, 2023 | 16.02% |
| Dec 31, 2022 | 25.73% |
| Sep 30, 2022 | 15.65% |
| Jun 30, 2022 | 10.02% |
| Mar 31, 2022 | 17.51% |
| Dec 31, 2021 | 25.43% |
| Sep 30, 2021 | 24.43% |
| Jun 30, 2021 | 32.17% |